We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2).
- Authors
Qaseem, Amir; Yost, Jennifer; Abraham, George M.; Andrews, Rebecca; Jokela, Janet A.; Miller, Matthew C.; Humphrey, Linda L.; Obley, Adam J.; Akl, Elie A.; Dunn, Andrew; Forciea, Mary Ann; Haeme, Ray; Kansagara, Devan L.; Lee, Rachael; Mackey, Katherine; Marcucci, Maura; Saini, Sameer D.; Tschanz, CDR Mark P.; Wilt, Timothy J.; Carroll, Kate
- Abstract
The Population Health and Medical Science Committee of the American College of Physicians (ACP) updates the living, rapid practice points on the treatment of adults with COVID-19 in an outpatient setting. Practice points are based on a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems. Description: Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. Methods: The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Practice Point 1: Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 2: Consider nirmatrelvir–ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 3: Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Practice Point 4: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
- Subjects
COVID-19 treatment; SARS-CoV-2 Omicron variant; PHYSICIANS; MEDICAL sciences; HEALTH policy
- Publication
Annals of Internal Medicine, 2023, Vol 176, Issue 10, p1396
- ISSN
0003-4819
- Publication type
Article
- DOI
10.7326/M23-1636